Richard King, MBA

Chief Executive Officer

Richard King’s career in the pharmaceutical and biotechnology sector spans 35 years, initially in marketing, then business development, and for the last 20 years in senior executive positions.  During that time, he has taken two companies public, has raised over $1bn in private and public company capital to further research, development and commercial efforts, and completed multiple company and product related business development transactions.

Most recently, Richard was Chief Executive Officer at Spruce Biosciences, holding executive responsibility for the strategic direction and program execution of a company focused on rare endocrine disorders.  Prior to that he was Chief Operating Officer at Adamas Pharmaceuticals, responsible for all operational aspects leading to the successful launch of a novel Parkinson’s disease medication.  Prior to that he was Chief Operating Officer at The Scripps Research Institute, responsible for strategic planning, business development, finance, human resources, facilities, information technology, and research services.  Prior to that, he was Chief Executive Officer of AcelRx Pharmaceuticals, a specialty pharmaceutical company developing new pain medications.   Richard received a B.Sc. (1st class) in chemical engineering from University of Surrey in the UK, and an M.B.A. from  Manchester Business School in the UK.

Daniel V. Santi, M.D., Ph.D

President and Chief Technical Officer (Co-Founder)

Dr. Santi received a Ph.D. in Medicinal Chemistry from SUNY in 1967 and a M.D. from UCSF in 1981. He was Assistant Professor of Chemistry at UCSB from 1968 to 1974. He joined the UCSF faculty in 1974 and was Professor of Biochemistry and Biophysics, and of Pharmaceutical Chemistry at UCSF until 2000 when he became CEO of Kosan Biosciences. He returned to UCSF in 2007 where he served as interim Director of the Clinical and Translational Science Institute and then Director of Translational Research at QB3. He became an Associate Dean for External Relationships in 2009, and has managed a successful Industry Outreach Program since that time. Dr. Santi has published over 300 scientific papers and is co-inventor on over 40 US patents.

Dan Santi was a member of the original Scientific Advisory Board of Chiron Corp. and has co-founded five biotechnology companies. In 1988, he founded and was Chairman of the peptide-combinatorial chemistry company Protos Corp., which merged with Chiron in 1992. He was a co-founder of Parnassus Pharmaceuticals, and of Prospect Genomics that merged with Structural Genomix in 2001. In 1996, he co-founded Kosan Biosciences where he served as CEO and Chairman until 2006; Kosan was acquired by Bristol Myers Squibb. During his tenure as CEO the company went public (NASDAQ), and four oncology compounds were brought into clinical trials. He co-founded the platform technology company ProLynx LLC in 2010, where he currently serves as President.

Gary W. Ashley, Ph.D

Chief Scientific Officer (Co-Founder)

Dr. Ashley received his S.B. in Chemistry from MIT in 1979, and his Ph.D. in Organic Chemistry from the University of California, Berkeley, in 1984. He was an Assistant Professor of Chemistry at Northwestern University, head of Chemistry at Parnassus Pharmaceuticals, Executive Director of Chemistry and then Vice President, Exploratory Research at Kosan Biosciences, Inc. Dr. Ashley is also a licensed patent agent with over eighteen years professional experience. He is co-author of over 70 scientific publications, and co-inventor on over 50 issued US patents.

Usha Arunachalam, Ph.D

Sr. Vice President, Business Development

Dr. Usha Arunachalam brings to ProLynx over 25 years of business development experience, primarily with early-staged biotechnology companies.  She has held senior management positions in various biotechnology companies.  Notably, she was Vice President of Business Development and Alliance Management for Research at the Leukemia, Lymphoma Society and was responsible for structuring the business terms for the Master Trial in AML and other impact investment opportunities.   She was Vice President of Business Development and led the business development and strategic efforts during the formative years of Five Prime Therapeutics.  Prior to FivePrime she was VP of Business Development at Intrabiotics, Sr. Director, Business Development at Kosan Biosciences and Associate Director at Chiron Corporation.  Dr. Arunachalam serves on the board of The Pacific Vision Foundation and chairs PVF’s Development Committee.  Dr. Arunachalam received her Ph.D. in Biochemistry from the Indian Institute of Science, Bangalore, India and her MBA from UCLA's Anderson School of Management.

Peter Langecker, M.D., Ph.D, Oncology

Advisor, Clinical Development

Dr. Langecker has over 25 years of experience in academic and industry-sponsored oncology/hematology clinical research and development Phase I to Phase IV, including the past 5 years at Clinipace as Medical Monitor and Executive Medical Director Global Oncology.  Peter's Pharmaceutical company experience includes Novartis, Schering-Plough, SUGEN (acquired by Pfizer) and several biotech companies. He contributed to the clinical development of Femara®, Eulexin®, Intron A®, Temodal®, Bexxar®, and Sutent® and is co-author of over 50 publications and posters.

Click here for more information: Board of Directors and Advisors.